SHORT REPORTS Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) is a nucleoside analogue that inhibits the replication of herpes simplex virus type 1 (HSV-1) in cell culture (primary rabbit kidney) at a concentration of 0 01 mg/l, but does not affect normal cell metabolism at concentrations up to 100 mg/I.' BVDU has also been found effective in the local and systemic treatment of HSV-1 skin lesions, and its associated mortality, in athymic nude mice' and in the local treatment of HSV-1 keratitis in rabbits.2 The compound is readily absorbed when given orally to mice3 or rabbits. BVDU doses of 500-1000 mg/kg body weight/day are well tolerated by mice, even if administered over 20 days.4
Recently we have found that BVDU is also highly active against varicella zoster virus, inhibiting the cytopathogenicity of this virus in human skin fibroblast cultures at a minimuim concentration of 0 004 to 0 04 mg/I. We now report on a clinical study with oral BVDU in the treatment of four patients with severe localised or disseminated herpes zoster.
Clinical details offour patients with herpes zoster given oral B VD U Case reports All four patients that were treated with BVDU (table) had severe localised or disseminated herpes zoster lesions, and three out of the four had a maligmant disorder for which they had been given intensive chemotherapy.
BVDU was administered by mouth at 7-5 mg/kg body weight/day (three or four capsules of 125 mg BVDU daily, eight or six hourly) for five days. Informed consent was obtained from all patients. The patients were examined daily during treatment and at regular intervals afterwards. Complete blood count; urea, creatinine, and electrolyte concentrations; and activities of liver enzymes (aspartate transaminase, alanine transaminase, and y-glutamic transpeptidase) were measured at the first, third, and fifth day of treatment. Drug concentrations in serum and urine were measured by bioassay, based on the inhibition of HSV-1 cytopathogenicity in cell culture.3
In all four patients progression of vesicle formation was completely arrested within 24 hours of starting treatment with BVDU: no new lesions developed during treatment, and the lesions which had developed before treatment healed briskly. For those patients (cases two and four) who presented with dissemination of the herpes zoster lesions, the prompt response to treatment was also reflected by a dramatic improvement in their general condition: fever resolved within 24 hours of starting treatment with BVDU. In case 4, where dissemination had occurred just before treatment, the newly formed lesions disappeared completely within two days of treatment. None of the patients who were treated with BVDU experienced any discomfort or showed any signs of drug toxicity. The biochemical and haematological blood values remained unchanged during the observation period. Plasma and urine concentrations of BVDU were measured in cases 1 and 3; the serum drug concentrations varied from 1 to 1-5 mg/l from one to three hours after BVDU administration. This concentration is about 100 times higher than the minimum effective dose required to inhibit VZV replication in cell culture. The urine drug concentrations were 10-15 mg/l In many forms of self-abuse noxious substances are inhaled. Although accidental exposure to chlorine gas from mixing household cleaning agents has been reported,' this patient inhaled chlorine for pleasure.
Case report
In November 1978 a 41-year-old electrician began mixing Vim and Ajax cleaning powders with water and sniffing the fumes released. He would occasionally heat the mixture to produce more fumes and would also smear the mixture over his arms. He was referred to the outpatient department in March 1979 with a six-week history of headache, sore eyes, swollen legs, and lethargy. He had no history of psychiatric illness or other forms of self-abuse, though he did smoke 20 cigarettes a day.
He had severe conjunctival injection, central cyanosis, a raised jugular venous pressure, gross oedema, and ascites. The heart was enlarged, the pulmonary second sound accentuated, and a third heart sound was audible.
Blood This prompted us to compare the psychiatric morbidity in women treated with a combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with that found in patients given melphalan or no further treatment. We also examined the relation between this morbidity and physical toxicity.
Patients, methods, and results
Half the weeks in a 24-month period were randomly selected. Women admitted in these weeks were included in the trial if their axillary lymph nodes were found at mastectomy to have been invaded by breast cancer (63 women), and they were randomised to receive CMF, melphalan, or no treatment (control subjects).
Trained interviewers administered the present-state examination shortly after surgery and three months and 12 to 18 months later to determine the incidence of psychiatric morbidity.3 They used a four-point scale (none to severe) to rate any physical toxicity, as did the clinicians following up these patients. Of the 63 patients, 59 completed all assessments.
Psychiatric morbidity-Of the 26 patients treated with CMF, 20 experienced an anxiety state compared with four of the 15 given melphalan and nine of the 18 control subjects ( patients given CMF (20 patients) than in the melphalan group (five patients) or control group (nine patients). Fourteen of the 20 patients given CMF who had a satisfactory sex life before mastectomy subsequently experienced a severe loss of interest compared with three of the eight patients given melphalan and five of the 10 control subjects. Twenty-one patients treated with CMF developed psychiatric morbidity during follow-up. Fewer patients given melphalan (five) and fewer control subjects (nine) did so. Physical toxicity-The clinicians and interviewers judged that 20 of the patients given CMF had experienced moderate or severe physical toxicity such as nausea or hair loss. Of these, 18 developed an anxiety state compared with two of the six patients with mild or minimal toxicity. The results for depressive illness were identical. Sexual problems occurred in 13 of the 15 patients with moderate or severe toxicity but in only two of the five patients who escaped it.
Disclosure of toxicity-The interviewers detected the toxicity in 18 of the 20 patients but the clinicians recognised it in only 12. Eight of these 12 reported the toxicity to a medical oncologist but not to the surgeons. Five of the eight patients who did not disclose toxicity failed to complete treatment compared with only two of the 12 who disclosed it.
Comment
Our sample is small, but our findings confirm a high incidence of psychiatric morbidity in patients given CMF and suggest that it is linked to physical toxicity.
The non-disclosure of toxicity is worrying, since it misleads clinicians about the consequences of treatment and results in poor compliance. It may explain the low toxicity reported in earlier studies. The greater honesty of patients with the medical oncologist may have reflected his skill in the use of cytotoxic drugs, his more detailed inquiry into toxicity, his sensitivity to cues given by the patients, and his greater awareness of barriers to communication.4
